To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

The Vietnam Hepatitis Treatment Market was valued at USD 146.25 million in 2023 and is projected to reach USD 197.35 million by 2029, growing at a CAGR of 5.08% during the forecast period. The ...

Hepatitis C Diagnosis and Treatment The hepatitis c diagnosis and treatment market size are predicted to develop because of the factors suc ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

HEV-specific antiviral treatment is still lacking. Here, the authors functionally and structurally characterize broadly neutralizing antibodies isolated from HEV convalescent individuals and show ...

The American Gastroenterological Association (AGA) has released an updated clinical practice guideline on the prevention of ...

Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal ...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $115.99, denoting a +1.47% change from the preceding trading day.

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Early efficacy results from a phase 2 trial last summer suggested the treatment may pose a threat to Gilead Sciences' stuttering attempt to capture the hepatitis D market. Hepatitis D can only ...